JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB3642

Anti-CDKN2A/p14ARF antibody

Be the first to review this product! Submit a review

|

(21 Publications)

Rabbit Polyclonal p14ARF antibody. Suitable for IHC-P, ICC/IF and reacts with Human samples. Cited in 21 publications.

View Alternative Names

CDKN2, MLM, CDKN2A, Tumor suppressor ARF, Alternative reading frame, Cyclin-dependent kinase inhibitor 2A, p14ARF, ARF

3 Images
Immunocytochemistry/ Immunofluorescence - Anti-CDKN2A/p14ARF antibody (AB3642)
  • ICC/IF

Unknown

Immunocytochemistry/ Immunofluorescence - Anti-CDKN2A/p14ARF antibody (AB3642)

ICC/IF image of ab3642 stained HeLa cells. The cells were 4% formaldehyde fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody ab3642 at 1μg/ml overnight at +4°C. The secondary antibody (green) was DyLight® 488 goat anti- rabbit (ab96899) IgG (H+L) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43μM.

Immunocytochemistry/ Immunofluorescence - Anti-CDKN2A/p14ARF antibody (AB3642)
  • ICC/IF

Lab

Immunocytochemistry/ Immunofluorescence - Anti-CDKN2A/p14ARF antibody (AB3642)

Confocal image showing nuclear staining increased after HeLa cells transfected with CDKN2A/p14ARF.

ICC/IF image of ab3642 stained HeLa cells. The cells were 4% paraformaldehyde fixed and then incubated in 0.1% trixtonX-100 to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with primary antibody ab3642 at a dilution of 1/250. An AlexaFluor®594 goat anti-mouse secondary IgG (ab150077) was used at a 1/1000 dilution. Anti-tubulin (ab7291) and an AlexaFluor®594 goat anti-mouse IgG (ab150120) were used as counterstains, both at a dilution of 1/1000. DAPI was used to stain the cell nuclei blue.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CDKN2A/p14ARF antibody (AB3642)
  • IHC-P

AbReview

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CDKN2A/p14ARF antibody (AB3642)

Immunohistochemical analysis of human cervical adenocarcinomas tissue labelling p14 with ab3642 at 1/200 dilution in PBS/1% BSA. Staining was most prominent in the nuclei but other staining, most likely aspecific staining, was observed in apical vacuoles.

Dilutions of 1/100, 1/200 and 1/400 were tested.
1/100 dilution was a bit too weak and 1/400 gave too much background so in the end the dilution of 1/200 in PBS containing 1% BSA was used.

Several heat induced antigen retrieval methods were used (citrate and EDTA-Tris, both in microwave and autoclave).

Image supplied as part of the review submitted by Joost van Galen.

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

ICC/IF, IHC-P

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/200", "IHCP-species-notes": "<p></p>", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "1 µg/mL", "ICCIF-species-notes": "<p></p>" } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Immunogen
Storage buffer
pH: 7.6 Preservative: 0.1% Sodium azide Constituents: PBS, 1% BSA
Shipped at conditions
Blue Ice
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Capable of inducing cell cycle arrest in G1 and G2 phases. Acts as a tumor suppressor. Binds to MDM2 and blocks its nucleocytoplasmic shuttling by sequestering it in the nucleolus. This inhibits the oncogenic action of MDM2 by blocking MDM2-induced degradation of p53 and enhancing p53-dependent transactivation and apoptosis. Also induces G2 arrest and apoptosis in a p53-independent manner by preventing the activation of cyclin B1/CDC2 complexes. Binds to BCL6 and down-regulates BCL6-induced transcriptional repression. Binds to E2F1 and MYC and blocks their transcriptional activator activity but has no effect on MYC transcriptional repression. Binds to TOP1/TOPOI and stimulates its activity. This complex binds to rRNA gene promoters and may play a role in rRNA transcription and/or maturation. Interacts with NPM1/B23 and promotes its polyubiquitination and degradation, thus inhibiting rRNA processing. Plays a role in inhibiting ribosome biogenesis, perhaps by binding to the nucleolar localization sequence of transcription termination factor TTF1, and thereby preventing nucleolar localization of TTF1 (By similarity). Interacts with COMMD1 and promotes its 'Lys63'-linked polyubiquitination. Interacts with UBE2I/UBC9 and enhances sumoylation of a number of its binding partners including MDM2 and E2F1. Binds to HUWE1 and represses its ubiquitin ligase activity. May play a role in controlling cell proliferation and apoptosis during mammary gland development.. Isoform smARF. May be involved in regulation of autophagy and caspase-independent cell death; the short-lived mitochondrial isoform is stabilized by C1QBP.
See full target information CDKN2A

Publications (21)

Recent publications for all applications. Explore the full list and refine your search

Cell biology and toxicology 40:24 PubMed38653919

2024

Elongin B promotes breast cancer progression by ubiquitinating tumor suppressor p14/ARF.

Applications

Unspecified application

Species

Unspecified reactive species

Xin-Yi Sui,Xiao-Yan Ma,Yujin Hou,Shuo-Wen Cao,Zhi-Qing Wang,Li-Jun Jia,Lei Fan,Zhi-Ming Shao,Wen-Juan Zhang

Medicine 102:e35531 PubMed37986346

2023

Differential expression of BCL11b and CDKN2A in CD30-positive peripheral T cell lymphoma: Retrospective study.

Applications

Unspecified application

Species

Unspecified reactive species

Yajing Wang,Fei Zhang,Ning Gao,Peng Bu,Wei Cui,Yanfeng Xi

Chemical & pharmaceutical bulletin 70:885-891 PubMed36450587

2022

Natural Compounds with BMI1 Promoter Inhibitory Activity from Mammea siamensis and Andrographis paniculata.

Applications

Unspecified application

Species

Unspecified reactive species

Kazuki Fujii,Yasumasa Hara,Midori A Arai,Samir K Sadhu,Firoj Ahmed,Masami Ishibashi

Frontiers in oncology 12:807597 PubMed36052249

2022

Heterotypic neutrophil-in-tumor structure: A novel pathological feature first discovered in the tissues of OPSCC.

Applications

Unspecified application

Species

Unspecified reactive species

Jie Fan,Peng Li,Qigen Fang,Yang Yang,He Zhang,Wei Du,Shanting Liu,Ruihua Luo

Cell death and differentiation : PubMed33504946

2021

Tumor-associated antigen Prame targets tumor suppressor p14/ARF for degradation as the receptor protein of CRL2 complex.

Applications

Unspecified application

Species

Unspecified reactive species

Wenjuan Zhang,Lihui Li,Lili Cai,Yupei Liang,Junfeng Xu,Yue Liu,Lisha Zhou,Chen Ding,Yanmei Zhang,Hu Zhao,Jun Qin,Zhimin Shao,Wenyi Wei,Lijun Jia

Pigment cell & melanoma research 32:474-478 PubMed30672662

2019

Biomarker discovery analysis: Alterations in p14, p16, p53, and BAP1 expression in nevi, cutaneous melanoma, and metastatic melanoma.

Applications

Unspecified application

Species

Unspecified reactive species

Michael R Sargen,Jeffrey M Cloutier,Kavita Y Sarin,Kerri E Rieger,Pauline Chu,Susan M Swetter,Roberto A Novoa

Journal of ovarian research 12:4 PubMed30651135

2019

Overexpression of CCDC69 activates p14/MDM2/p53 pathway and confers cisplatin sensitivity.

Applications

Unspecified application

Species

Unspecified reactive species

Long Cui,Fang Zhou,Cui Chen,Chi Chiu Wang

Oncogenesis 7:50 PubMed29904067

2018

CDKN2A inhibits formation of homotypic cell-in-cell structures.

Applications

Unspecified application

Species

Unspecified reactive species

Jianqing Liang,Jie Fan,Manna Wang,Zubiao Niu,Zhengrong Zhang,Long Yuan,Yanhong Tai,Zhaolie Chen,Santai Song,Xiaoning Wang,Xiaoqing Liu,Hongyan Huang,Qiang Sun

Oncology letters 15:2795-2800 PubMed29435006

2018

PRL-3 promotes breast cancer progression by downregulating p14-mediated p53 expression.

Applications

Unspecified application

Species

Unspecified reactive species

Hua Xie,Hao Wang

Oncotarget 7:78095-78109 PubMed27801668

2016

Upregulation of miR-99a is associated with poor prognosis of acute myeloid leukemia and promotes myeloid leukemia cell expansion.

Applications

WB

Species

Human

Xiaohui Si,Xiaoyun Zhang,Xing Hao,Yunan Li,Zizhen Chen,Yahui Ding,Hui Shi,Jie Bai,Yingdai Gao,Tao Cheng,Feng-Chun Yang,Yuan Zhou
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com